GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OTCPK:BVNRY) » Definitions » Capex-to-Revenue

Bavarian Nordic A/S (Bavarian Nordic A/S) Capex-to-Revenue : 0.10 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Bavarian Nordic A/S Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Bavarian Nordic A/S's Capital Expenditure for the three months ended in Dec. 2023 was $-35.72 Mil. Its Revenue for the three months ended in Dec. 2023 was $358.06 Mil.

Hence, Bavarian Nordic A/S's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.10.


Bavarian Nordic A/S Capex-to-Revenue Historical Data

The historical data trend for Bavarian Nordic A/S's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bavarian Nordic A/S Capex-to-Revenue Chart

Bavarian Nordic A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.03 0.38 0.56 0.44 0.14

Bavarian Nordic A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.19 0.16 0.13 0.10

Competitive Comparison of Bavarian Nordic A/S's Capex-to-Revenue

For the Biotechnology subindustry, Bavarian Nordic A/S's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bavarian Nordic A/S's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bavarian Nordic A/S's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bavarian Nordic A/S's Capex-to-Revenue falls into.



Bavarian Nordic A/S Capex-to-Revenue Calculation

Bavarian Nordic A/S's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-143.004) / 1033.291
=0.14

Bavarian Nordic A/S's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-35.721) / 358.059
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bavarian Nordic A/S  (OTCPK:BVNRY) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Bavarian Nordic A/S Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bavarian Nordic A/S's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bavarian Nordic A/S (Bavarian Nordic A/S) Business Description

Traded in Other Exchanges
Address
Philip Heymans Alle 3, Hellerup, DNK, DK-2900
Bavarian Nordic A/S is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets.

Bavarian Nordic A/S (Bavarian Nordic A/S) Headlines

From GuruFocus

Q1 2021 Bavarian Nordic A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024

Bavarian Nordic A/S - Special Call Transcript

By GuruFocus Research 02-13-2024

Bavarian Nordic A/S Conference Call Transcript

By GuruFocus Research 02-13-2024

Bavarian Nordic A/S - Special Call Transcript

By GuruFocus Research 02-13-2024

Q3 2023 Bavarian Nordic A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024

Bavarian Nordic A/S - Special Call Transcript

By GuruFocus Research 02-13-2024

Q4 2018 Bavarian Nordic A/S Earnings Call Transcript

By GuruFocus Research 02-13-2024